Molecular Diagnostics uses analysis of DNA, RNA and other molecular components to detect, characterise or monitor disease. It includes techniques that identify genetic variants, pathogen nucleic acids, gene expression patterns, chromosomal changes and other molecular biomarkers. The field has transformed diagnosis by allowing diseases to be distinguished according to underlying molecular mechanisms rather than solely by symptoms or visible anatomy. Molecular tests can be used for inherited disorders, infectious diseases, cancer, pharmacogenomics and other clinical applications. Technologies range from targeted amplification assays to high throughput sequencing and other advanced platforms, with the appropriate method determined by the clinical question and the type of molecular alteration being investigated.
Polymerase chain reaction is a foundational molecular diagnostic technique that amplifies selected DNA sequences so that they can be detected and analysed. Reverse transcription polymerase chain reaction can be used when the starting material is RNA by first producing complementary DNA. Quantitative amplification methods can estimate the amount of target nucleic acid present, allowing applications such as monitoring certain infections or measuring specific molecular signals. Assay design determines which sequences can be detected, and primers, probes and controls must be carefully selected. Molecular amplification is highly sensitive but can be affected by contamination, inhibitors, poor specimen quality and inappropriate target selection.
Sequencing technologies allow determination of nucleotide sequences and identification of genetic variants. Sanger sequencing is useful for many targeted applications, while next generation sequencing can analyse many genes or large portions of the genome simultaneously. Targeted panels focus sequencing capacity on clinically relevant genes, whereas broader approaches can examine exomes or entire genomes. Sequencing results require bioinformatic processing to identify candidate variants, followed by annotation and clinical interpretation. Detection alone does not establish pathogenicity because genetic variation includes benign, uncertain and disease associated changes. Molecular diagnostic laboratories therefore integrate sequence evidence with population databases, functional studies, clinical information and established classification frameworks.
Molecular Diagnostics is particularly important in oncology. Tumours can be analysed for mutations, amplifications, deletions, rearrangements, fusions and other alterations that affect classification or treatment. Molecular testing may identify biomarkers associated with targeted therapies or reveal mechanisms of treatment resistance. Testing can be performed on tissue, blood or other specimens depending on the clinical question. Liquid biopsy approaches can analyse circulating tumour DNA, although detection depends on tumour shedding, disease burden and assay sensitivity. Tumour heterogeneity means that a negative molecular result from one specimen does not necessarily prove the absence of an alteration throughout the entire tumour population.
Infectious disease is another major application of Molecular Diagnostics. Nucleic acid amplification tests can detect pathogen genetic material and can be highly sensitive and specific when appropriately designed and validated. Molecular methods can be faster than culture for certain organisms and may detect pathogens that are difficult to grow. Multiplex assays can detect multiple targets simultaneously, although increased breadth can introduce interpretation challenges and may detect organisms whose clinical significance is uncertain. Molecular detection does not always prove that an organism is viable or that it is the cause of symptoms. Results therefore require consideration of specimen type, timing, clinical presentation and the biological behaviour of the organism.
Molecular diagnostic quality depends on specimen selection, nucleic acid extraction, assay design, controls, contamination prevention and interpretation. Preanalytical problems can produce false negative results through degradation or inadequate target material. Analytical problems can arise from inhibitors, sequence variation at primer binding sites, insufficient assay coverage or technical errors. Positive controls demonstrate that the assay can detect its intended target, while negative controls help identify contamination. Laboratories must validate assays for intended clinical use and establish analytical performance characteristics such as sensitivity, specificity, precision and detection limits. Clinical validity and clinical utility are separate considerations because a technically accurate test is not necessarily useful for a particular clinical decision.
Pharmacogenomics uses molecular information to investigate how genetic variation influences drug response. Variants in genes involved in drug metabolism, transport or drug targets can sometimes affect efficacy or toxicity and may inform treatment selection. Molecular diagnostics can also identify inherited variants associated with disease susceptibility or reproductive considerations. Germline testing differs from somatic tumour testing because germline findings may have implications for relatives and are present throughout the body, while somatic findings are acquired and restricted to particular cell populations. Careful consent, interpretation and communication are therefore important, especially when testing may reveal unexpected hereditary information.
Molecular Diagnostics continues to develop through increasingly comprehensive sequencing, digital methods, liquid biopsy, single cell analysis and integrated genomic approaches. Greater analytical power produces both opportunities and challenges because broader testing increases the probability of identifying variants whose significance is uncertain. Data interpretation requires reliable reference databases, validated pipelines and appropriate clinical expertise. A common misconception is that molecular tests are inherently more accurate than all other diagnostic methods. Their performance depends on the assay, specimen, target and clinical setting. Molecular information is most valuable when integrated with pathology, imaging, laboratory findings and clinical evidence to answer a clearly defined diagnostic or management question.
